ASX - By Stock
|
WBT |
Re:
Weebit - 2024 and beyond
|
|
pinch2020
|
1.2K |
488K |
15 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
1.2K
|
488K
|
15
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
pinch2020
|
692 |
275K |
3 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
692
|
275K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
pinch2020
|
422 |
146K |
2 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
422
|
146K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
pinch2020
|
692 |
275K |
10 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
692
|
275K
|
10
|
|
ASX - By Stock
|
WBT |
Re:
WBT Industry Related Off Topic.
|
|
pinch2020
|
1.2K |
546K |
20 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
1.2K
|
546K
|
20
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
pinch2020
|
422 |
146K |
10 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
422
|
146K
|
10
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2024 and beyond
|
|
pinch2020
|
1.2K |
488K |
22 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
1.2K
|
488K
|
22
|
|
ASX - By Stock
|
CHM |
Re:
Ann: US patent allowed for CHM 0201 (CORE-NK) technology
|
|
pinch2020
|
15 |
5.2K |
4 |
07/04/24 |
07/04/24 |
ASX - By Stock
|
15
|
5.2K
|
4
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2024 and beyond
|
|
pinch2020
|
1.2K |
488K |
0 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
1.2K
|
488K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
pinch2020
|
692 |
275K |
6 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
692
|
275K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
pinch2020
|
40 |
16K |
9 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
40
|
16K
|
9
|
|
ASX - By Stock
|
WBT |
Re:
WBT Industry Related Off Topic.
|
|
pinch2020
|
1.2K |
546K |
6 |
01/04/24 |
01/04/24 |
ASX - By Stock
|
1.2K
|
546K
|
6
|
|
ASX - By Stock
|
WBT |
Re:
WBT Industry Related Off Topic.
|
|
pinch2020
|
1.2K |
546K |
7 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
1.2K
|
546K
|
7
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
pinch2020
|
40 |
16K |
4 |
23/03/24 |
23/03/24 |
ASX - By Stock
|
40
|
16K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Chimeric to present at NWR Virtual Healthcare Conference
|
|
pinch2020
|
22 |
7.2K |
2 |
23/03/24 |
23/03/24 |
ASX - By Stock
|
22
|
7.2K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Clinical milestones for 2024 & 2023 successes highlighted
|
|
pinch2020
|
26 |
9.1K |
2 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
26
|
9.1K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Clinical milestones for 2024 & 2023 successes highlighted
|
|
pinch2020
|
26 |
9.1K |
6 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
26
|
9.1K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Clinical milestones for 2024 & 2023 successes highlighted
|
|
pinch2020
|
26 |
9.1K |
3 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
26
|
9.1K
|
3
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Weebit Nano Investor Presentation
|
|
pinch2020
|
184 |
70K |
25 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
184
|
70K
|
25
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Clinical milestones for 2024 & 2023 successes highlighted
|
|
pinch2020
|
26 |
9.1K |
8 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
26
|
9.1K
|
8
|
|
ASX - By Stock
|
CHM |
Re:
Ann: New data for Phase 1A CLTX CAR T brain cancer clinical trial
|
|
pinch2020
|
75 |
25K |
2 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
75
|
25K
|
2
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2024 and beyond
|
|
pinch2020
|
1.2K |
488K |
4 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
1.2K
|
488K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
pinch2020
|
40 |
16K |
4 |
09/03/24 |
09/03/24 |
ASX - By Stock
|
40
|
16K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
pinch2020
|
40 |
16K |
0 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
40
|
16K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: New data for Phase 1A CLTX CAR T brain cancer clinical trial
|
|
pinch2020
|
75 |
25K |
4 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
75
|
25K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
pinch2020
|
40 |
16K |
6 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
40
|
16K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
pinch2020
|
40 |
16K |
3 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
40
|
16K
|
3
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Structural Monitoring Systems Investor Webinar
|
|
pinch2020
|
121 |
32K |
4 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
121
|
32K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
pinch2020
|
422 |
146K |
7 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
422
|
146K
|
7
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Chimeric to present at ********* Hidden Gems webinar
|
|
pinch2020
|
17 |
5.4K |
5 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
17
|
5.4K
|
5
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2024 and beyond
|
|
pinch2020
|
1.2K |
488K |
2 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
1.2K
|
488K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
biotech could be sector for 2024
|
|
pinch2020
|
10 |
4.3K |
9 |
25/02/24 |
25/02/24 |
ASX - By Stock
|
10
|
4.3K
|
9
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
pinch2020
|
40 |
16K |
6 |
23/02/24 |
23/02/24 |
ASX - By Stock
|
40
|
16K
|
6
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2024 and beyond
|
|
pinch2020
|
1.2K |
488K |
40 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
1.2K
|
488K
|
40
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2024 and beyond
|
|
pinch2020
|
1.2K |
488K |
15 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
1.2K
|
488K
|
15
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2024 and beyond
|
|
pinch2020
|
1.2K |
488K |
53 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
1.2K
|
488K
|
53
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2024 and beyond
|
|
pinch2020
|
1.2K |
488K |
7 |
20/02/24 |
20/02/24 |
ASX - By Stock
|
1.2K
|
488K
|
7
|
|
ASX - By Stock
|
CHM |
Re:
biotech could be sector for 2024
|
|
pinch2020
|
10 |
4.3K |
5 |
20/02/24 |
20/02/24 |
ASX - By Stock
|
10
|
4.3K
|
5
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Structural Monitoring Systems Investor Webinar
|
|
pinch2020
|
121 |
32K |
9 |
20/02/24 |
20/02/24 |
ASX - By Stock
|
121
|
32K
|
9
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
pinch2020
|
692 |
275K |
9 |
18/02/24 |
18/02/24 |
ASX - By Stock
|
692
|
275K
|
9
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
pinch2020
|
692 |
275K |
4 |
18/02/24 |
18/02/24 |
ASX - By Stock
|
692
|
275K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
pinch2020
|
692 |
275K |
10 |
14/02/24 |
14/02/24 |
ASX - By Stock
|
692
|
275K
|
10
|
|
ASX - By Stock
|
CHM |
Re:
biotech could be sector for 2024
|
|
pinch2020
|
10 |
4.3K |
8 |
13/02/24 |
13/02/24 |
ASX - By Stock
|
10
|
4.3K
|
8
|
|
ASX - By Stock
|
CHM |
Re:
biotech could be sector for 2024
|
|
pinch2020
|
10 |
4.3K |
16 |
09/02/24 |
09/02/24 |
ASX - By Stock
|
10
|
4.3K
|
16
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
pinch2020
|
40 |
16K |
8 |
08/02/24 |
08/02/24 |
ASX - By Stock
|
40
|
16K
|
8
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
pinch2020
|
40 |
16K |
6 |
08/02/24 |
08/02/24 |
ASX - By Stock
|
40
|
16K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
Ann: New data for Phase 1A CLTX CAR T brain cancer clinical trial
|
|
pinch2020
|
75 |
25K |
2 |
07/02/24 |
07/02/24 |
ASX - By Stock
|
75
|
25K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: New data for Phase 1A CLTX CAR T brain cancer clinical trial
|
|
pinch2020
|
75 |
25K |
4 |
06/02/24 |
06/02/24 |
ASX - By Stock
|
75
|
25K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
pinch2020
|
34 |
10K |
2 |
01/02/24 |
01/02/24 |
ASX - By Stock
|
34
|
10K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: ADVENT-AML Phase 1B clinical trial open to enrolment
|
|
pinch2020
|
24 |
7.4K |
4 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
24
|
7.4K
|
4
|
|